Novel Treatments for Drug-Resistant Tuberculosis

被引:5
作者
Clain, Jeremy M. [1 ,2 ]
Escalante, Patricio [1 ,2 ,3 ]
机构
[1] Mayo Clin, Div Pulm & Crit Care Med, Mycobacterial & Bronchiectasis Clin, Rochester, MN 55905 USA
[2] Olmsted Cty Publ Hlth TB Clin, Rochester, MN 55904 USA
[3] Mayo Clin, Mayo Clin Ctr TB, Rochester, MN USA
关键词
tuberculosis; drug resistance; multidrug-resistant; antitubercular agents; novel drugs;
D O I
10.4137/CMT.S18560
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug resistance has emerged as a major obstacle to global control of tuberculosis (TB). Treatment with currently available medications requires prolonged courses of numerous drugs, many of which are associated with significant adverse effects. New drugs are urgently needed to meet the challenge posed by drug-resistant TB, in order to relieve the burden that drug resistance has placed on individual patients and health systems. Fortunately, many new drugs have been developed for the treatment of drug-resistant TB in recent years. The new antimycobacterial agents are derived from various medication classes, work by means of an assortment of mechanisms of action, and are at differing phases of development. This review provides a survey of the most promising new agents, in order to promote familiarity with these emerging drugs and compounds.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 52 条
[1]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[2]  
[Anonymous], 2014, Drug Ther Bull, V52, P129, DOI 10.1136/dtb.2014.11.0291
[3]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[4]   Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients [J].
Aung, K. J. M. ;
Van Deun, A. ;
Declercq, E. ;
Sarker, M. R. ;
Das, P. K. ;
Hossain, M. A. ;
Rieder, H. L. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (10) :1180-1187
[5]   Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis [J].
Balasubramanian, V. ;
Solapure, S. ;
Iyer, H. ;
Ghosh, A. ;
Sharma, S. ;
Kaur, P. ;
Deepthi, R. ;
Subbulakshmi, V. ;
Ramya, V. ;
Ramachandran, V. ;
Balganesh, M. ;
Wright, L. ;
Melnick, D. ;
Butler, S. L. ;
Sambandamurthy, V. K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) :495-502
[6]   Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity [J].
Barbachyn, MR ;
Hutchinson, DK ;
Brickner, SJ ;
Cynamon, MH ;
Kilburn, JO ;
Klemens, SP ;
Glickman, SE ;
Grega, KC ;
Hendges, SK ;
Toops, DS ;
Ford, CW ;
Zurenko, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :680-685
[7]   INFECTIOUS DISEASE Approval of Novel TB Drug Celebrated-With Restraint [J].
Cohen, Jon .
SCIENCE, 2013, 339 (6116) :130-130
[8]   TB - A new target, a new drug [J].
Cole, ST ;
Alzari, PM .
SCIENCE, 2005, 307 (5707) :214-215
[9]   USPHS TUBERCULOSIS SHORT-COURSE CHEMOTHERAPY TRIAL-21 - EFFECTIVENESS, TOXICITY, AND ACCEPTABILITY - THE REPORT OF FINAL RESULTS [J].
COMBS, DL ;
OBRIEN, RJ ;
GEITER, LJ .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :397-406
[10]   Management of Multidrug Resistant Tuberculosis Preface [J].
Daley, Charles L. ;
Caminero, Jose A. .
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 34 (01) :44-59